Table 1.

Patient, disease and treatment characteristics of the entire cohort, surgery and no surgery groups.

		All n=172		Surgery n=79		No Surgery n=93		p Value¶
Age
	Average	52		51		53		.38
	Range	22-85		22-78		26-85
Race
	White	119	69%	60	76%	59	63%	0.2
	Black	32	19%	11	14%	21	23%
	Other	21	12%	8	10%	13	14%
ECOG Performance Status
	0-1	126	73%	72	91%	54	58%	<0.0001
	>1	29	17%	4	5%	25	27%
	Unknown	17	10%	3	4%	14	15%
Menopausal status*
	Post	100	58%	44	56%	56	60%	0.38
	Pre	69	40%	35	44%	34	37%
Hormone receptor*
	Pos	89	52%	43	54%	46	49%	0.59
	Neg	77	45%	34	43%	43	46%
HER2 receptor*							1
	Pos	45	26%	27	34%	18	19%	0.02
	Neg	117	68%	47	59%	70	75%
Grade*
	1	3	2%	1	1%	2	2%	0.57
	2	38	22%	15	19%	23	25%
	3	120	70%	58	73%	62	67%
LVSI
	Yes	78	45%	49	62%	29	31%	0.33
	No	39	23%	28	35%	11	12%
	Unknown	55	32%	2	3%	53	57%
Histology
	Ductal	136	79%	64	81%	72	77%	0.22
	Lobular	13	8%	8	10%	5	5%
	Mixed	14	8%	4	5%	10	11%
Systemic therapy
	Chemo only	117	68%	45	57%	72	77%	0.006
	chemo+endocrine	55	32%	34	43%	21	23%
Response to systemic therapy
	Non-responders	69	40%	10	13%	59	63%	<.0001
	Responders	98	56%	67	85%	31	34%
Locoregional therapy
	None	75	44%
	Radiotherapy alone	18	10%
	Surgery alone	11	6%
	Surgery+radiotherapy	68	40%
Surgical intent
	Curative			47	59%
	Local control			32	41%
Margin status*
	Negative			60	87%
	Positive			7	4%
	Close			8	6%
pCR
	Yes			12	15%
	No			67	85%
# distant disease sites
	1	94	55%	59	75%	35	38%
	>1	78	45%	20	25%	58	62%

^*Unknown values were omitted when they accounted for ≤6% of patients, thus percentages displayed may not total 100%.

^¶p value is between surgery and no surgery groups

Abbreviations: ECOG, Eastern Cooperative Oncology Group; LVSI, lymphovascular space invasion; pCR pathologic complete response